Genetically engineered SCN5A mutant pig hearts exhibit conduction defects and arrhythmias

Journal of Clinical Investigation

Volumn 125, Issue 1, 2015, Pages 403-412

  Park, David S ^a   Cerrone, Marina ^a   Morley, Gregory ^a   Vasquez, Carolina ^a   Fowler, Steven ^a   Liu, Nian ^a   Bernstein, Scott A ^a   Liu, Fang Yu ^a   Zhang, Jie ^a   Rogers, Christopher S ^b   Priori, Silvia G ^a,c   Chinitz, Larry A ^a   Fishman, Glenn I ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Exemplar Genetics   (United States)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; ANKYRIN G; CONNEXIN 43; DESMOPLAKIN; FLECAINIDE; NERVE CELL ADHESION MOLECULE; PLAKOPHILIN; PLAKOPHILIN 2; PROTEIN ZO1; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL; STOP CODON;

ACTION POTENTIAL DURATION; ADULT; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRUGADA SYNDROME; CARDIAC CHANNELOPATHY; CELL NUCLEUS TRANSPLANTATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; ELECTROCARDIOGRAM; EMBRYO; EMBRYO TRANSFER; FEMALE; HEART ARRHYTHMIA; HEART CONDUCTION; HEART DEPOLARIZATION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART REPOLARIZATION; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE EXTRASYSTOLE; HUMAN; IMMUNOLOCALIZATION; IN VIVO STUDY; MALE; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; PROPENSITY SCORE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PURKINJE FIBER; QRS COMPLEX; SINUS NODE RECOVERY TIME; SODIUM CHANNELOPATHY; SODIUM CONDUCTANCE; STOP CODON; TRANSITION TEMPERATURE; TRANSTHORACIC ECHOCARDIOGRAPHY; WENCKEBACH PERIOD; WESTERN BLOTTING; YUCATAN MICROPIG; ANIMAL; CONGENITAL MALFORMATION; DISEASE MODEL; GENETIC ENGINEERING; GENETICS; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; SWINE;

ANIMALS; ARRHYTHMIAS, CARDIAC; BASE SEQUENCE; BRUGADA SYNDROME; CODON, NONSENSE; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HEART CONDUCTION SYSTEM; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; NAV1.5 VOLTAGE-GATED SODIUM CHANNEL; SUS SCROFA;

EID: 84920392859     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76919     Document Type: Article

References (44)

1. Probst V, et al. Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. J Am Coll Cardiol. 2003;41(4):643-652.
2. Kyndt F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001;104(25):3081-3086.
3. Chen Q, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392(6673):293-296.
4. Amin AS, et al. Facilitatory and inhibitory effects of SCN5A mutations on atrial fibrillation in Bru-gada syndrome. Europace. 2011;13(7):968-975.
5. McNair WP, et al. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol. 2011;57(21):2160-2168.
6. Antzelevitch C, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111(5):659-670.
7. Ackerman MJ, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077-1109.
8. Chockalingam P, et al. The diagnostic and therapeutic aspects of loss-of-function cardiac sodium channelopathies in children. Heart Rhythm. 2012;9(12):1986-1992.
9. Watanabe H, et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular fibrillation associated with early repolarization. Circ Arrhythm Electrophysiol. 2011;4(6):874-881.
10. Zumhagen S, et al. A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss-and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome. PLoS One. 2013;8(6):e67963.
11. Rogers CS, et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest. 2008;118(4):1571-1577.
12. Stubhan M, et al. Evaluation of cardiovascular and ECG parameters in the normal, freely moving Gottingen Minipig. J Pharmacol Toxicol Methods. 2008;57(3):202-211.
13. Maury P, et al. Prevalence and prognostic role of various conduction disturbances in patients with the brugada syndrome. Am J Cardiol. 2013;112(9):1384-1389.
14. Probst V, et al. Progressive cardiac conduction defect is the prevailing phenotype in carriers of a Brugada syndrome SCN5A mutation. J Cardiovasc Electrophysiol. 2006;17(3):270-275.
15. Brugada R, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101(5):510-515.
16. Cerrone M, Delmar M. Desmosomes and the sodium channel complex: implications for arrhythmogenic cardiomyopathy and Brugada syndrome. Trends Cardiovasc Med. 2014;24(5):184-190.
17. Delmar M. Connexin43 regulates sodium current; ankyrin-G modulates gap junctions: the intercalated disc exchanger. Cardiovasc Res. 2012;93(2):220-222.
18. Jansen JA, et al. Reduced heterogeneous expression of Cx43 results in decreased Nav1.5 expression and reduced sodium current which accounts for arrhythmia vulnerability in conditional Cx43 knockout mice. Heart Rhythm. 2012;9(4):600-607.
19. Sato PY, et al. Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myo-cytes. Circ Res. 2009;105(6):523-526.
20. Milstein ML, et al. Dynamic reciprocity of sodium and potassium channel expression in a macromolecular complex controls cardiac excitability and arrhythmia. Proc Natl Acad Sci U S A. 2012;109(31):E2134-E2143.
21. Wilde AA, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol. 2010;49(4):543-553.
22. Schott JJ, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999;23(1):20-21.
23. Lev M. Anatomic basis for atrioventricular block. Am J Med. 1964;37(5):742-748.
24. Li GR, Du XL, Siow YL, O K, Tse HF, Lau CP. Calcium-activated transient outward chloride current and phase 1 repolarization of swine ventricular action potential. Cardiovasc Res. 2003;58(1):89-98.
25. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation. 1996;93(2):372-379.
26. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100(15):1660-1666.
27. Nademanee K, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011;123(12):1270-1279.
28. Frustaci A, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. Circulation. 2005;112(24):3680-3687.
29. Bezzina CR, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013;45(9):1044-1049.
30. Gang ES, Priori SS, Chen PS. Short coupled premature ventricular contraction initiating ventricular fibrillation in a patient with Bru-gada syndrome. J Cardiovasc Electrophysiol. 2004;15(7):837.
31. Kakishita M, et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol. 2000;36(5):1646-1653.
32. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Int Med. 2008;149(3):216-218.
33. Antzelevitch C, Brugada R. Fever and Bru-gada syndrome. Pacing Clin Electrophysiol. 2002;25(11):1537-1539.
34. Keller DI, et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. Cardiovasc Res. 2005;67(3):510-519.
35. Krauchi K, Wirz-Justice A. Circadian rhythm of heat production, heart rate, and skin and core temperature under unmasking conditions in men. Am J Physiol. 1994;267(3 Pt 2):R819-R829.
36. Dumaine R, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85(9):803-809.
37. Mok NS, Priori SG, Napolitano C, Chan NY, Chahine M, Baroudi G. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electro-physiol. 2003;14(4):407-411.
38. Clatot J, et al. Dominant-negative effect of SCN5A N-terminal mutations through the interaction of Na(v)1.5 alpha-subunits. Cardiovasc Res. 2012;96(1):53-63.
39. Noda T, et al. Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005;46(7):1288-1294.
40. Boyle PM, Park CJ, Arevalo HJ, Vigmond EJ, Tray-anova NA. Sodium current reduction unmasks a structure-dependent substrate for arrhyth-mogenesis in the normal ventricles. PLoS One. 2014;9(1):e86947.
41. Poletto R, et al. Identification of low and high frequency ranges for heart rate variability and blood pressure variability analyses using pharmacological autonomic blockade with atropine and propranolol in swine. Physiol Behav. 2011;103(2):188-196.
42. Sosa E, Scanavacca M, d'Avila A, Pilleggi F. A new technique to perform epicardial mapping in the electrophysiology laboratory. J Cardiovasc Elec-trophysiol. 1996;7(6):531-536.
43. Bustamante JO, Watanabe T, Murphy DA, McDonald TF. Isolation of single atrial and ventricular cells from the human heart. Can Med Assoc J. 1982;126(7):791-793.
44. Pandit SV, et al. Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs. Cardiovasc Res. 2011;89(4):843-851.